Stock Scorecard



Stock Summary for Corbus Pharmaceuticals Holdings Inc (CRBP) - $8.89 as of 7/21/2025 7:55:56 AM EST

Total Score

11 out of 30

Safety Score

36 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CRBP

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CRBP

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CRBP

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CRBP

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CRBP (36 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 5
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 3
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for CRBP

Cannabis Stock Gainers And Losers From July 16, 2025 - Blueberries Medical ( OTC:BBRRF ) , Belgravia Hartford Cap ( OTC:BLGVF ) 7/16/2025 8:32:00 PM
Cannabis Stock Movers For July 15, 2025 - Cannabix Technologies ( OTC:BLOZF ) , Belgravia Hartford Cap ( OTC:BLGVF ) 7/15/2025 8:30:00 PM
Bullish Sentiment Across The Cannabis Space - Check Full Movers For July 9, 2025 - Cannabix Technologies ( OTC:BLOZF ) , Belgravia Hartford Cap ( OTC:BLGVF ) 7/9/2025 8:30:00 PM
Marijuana Stock Movers For July 2, 2025 - Belgravia Hartford Cap ( OTC:BLGVF ) , Target Group ( OTC:CBDY ) 7/2/2025 8:31:00 PM
Cannabis Stock Movers For June 30, 2025 - Auxly Cannabis Group ( OTC:CBWTF ) , Blueberries Medical ( OTC:BBRRF ) 6/30/2025 8:30:00 PM
Cannabis Stock Movers For June 27, 2025 - Corbus Pharmaceuticals ( NASDAQ:CRBP ) , Cipher Pharmaceuticals ( OTC:CPHRF ) 6/27/2025 8:30:00 PM
Cannabis Stock Gainers And Losers From June 26, 2025 - Aurora Cannabis ( NASDAQ:ACB ) , Belgravia Hartford Cap ( OTC:BLGVF ) 6/26/2025 8:31:00 PM
Cannabis Stock Gainers And Losers From June 25, 2025 - Belgravia Hartford Cap ( OTC:BLGVF ) , Target Group ( OTC:CBDY ) 6/25/2025 8:30:00 PM
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab 6/25/2025 12:00:00 PM
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium 6/24/2025 8:05:00 PM

Financial Details for CRBP

Company Overview

Ticker CRBP
Company Name Corbus Pharmaceuticals Holdings Inc
Country USA
Description Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. The company is headquartered in Norwood, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 8.89
Price 4 Years Ago 18.47
Last Day Price Updated 7/21/2025 7:55:56 AM EST
Last Day Volume 62,570
Average Daily Volume 185,593
52-Week High 61.90
52-Week Low 4.64
Last Price to 52 Week Low 91.59%

Valuation Measures

Trailing PE N/A
Industry PE 22.09
Sector PE 40.31
5-Year Average PE -1.91
Free Cash Flow Ratio 5.77
Industry Free Cash Flow Ratio 17.52
Sector Free Cash Flow Ratio 32.27
Current Ratio Most Recent Quarter 11.82
Total Cash Per Share 1.54
Book Value Per Share Most Recent Quarter 10.39
Price to Book Ratio 0.82
Industry Price to Book Ratio 34.13
Sector Price to Book Ratio 30.89
Price to Sales Ratio Twelve Trailing Months 163.32
Industry Price to Sales Ratio Twelve Trailing Months 133.99
Sector Price to Sales Ratio Twelve Trailing Months 38.93
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 12,236,800
Market Capitalization 108,785,152
Institutional Ownership 93.23%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 9.85%
Reported EPS 12 Trailing Months -4.24
Reported EPS Past Year -1.39
Reported EPS Prior Year -3.66
Net Income Twelve Trailing Months -50,288,000
Net Income Past Year -40,209,000
Net Income Prior Year -44,603,316
Quarterly Revenue Growth YOY -100.00%
5-Year Revenue Growth -100.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 18,900,000
Total Cash Past Year 17,198,000
Total Cash Prior Year 13,723,681
Net Cash Position Most Recent Quarter 18,900,000
Net Cash Position Past Year 17,198,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 17,893,738
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 142,428,000
Total Stockholder Equity Prior Year -6,904,722
Total Stockholder Equity Most Recent Quarter 127,106,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -50,247,636
Free Cash Flow Per Share Twelve Trailing Months -4.11
Free Cash Flow Past Year -41,794,000
Free Cash Flow Prior Year -36,100,476

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.09
MACD Signal 0.02
20-Day Bollinger Lower Band 4.97
20-Day Bollinger Middle Band 7.23
20-Day Bollinger Upper Band 9.48
Beta 3.12
RSI 56.14
50-Day SMA 17.51
150-Day SMA 16.05
200-Day SMA 15.99

System

Modified 7/18/2025 9:07:33 PM EST